Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNJ11 | Q14654 | 16/20 | 0.69 |
| ▸ | ABCC9 | O60706 | 15/20 | 0.69 |
| ▸ | ABCC8 | Q09428 | 11/20 | 0.69 |
| ▸ | KCNJ8 | Q15842 | 11/20 | 0.69 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.54 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.54 |
| ▸ | NAMPT | P43490 | 1/20 | 0.52 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4679472 | 1.00 | KCNJ11 (0.69) | KCNJ11ABCC9ABCC8KCNJ8CYP11B1 | |
| SCHEMBL4678190 | 0.93 | KCNJ11 (0.67) | KCNJ11ABCC9ABCC8KCNJ8CYP11B1 | |
| SCHEMBL4266846 | 0.93 | KCNJ11 (0.67) | KCNJ11ABCC9ABCC8KCNJ8CYP11B1 | |
| SCHEMBL4266843 | 0.93 | KCNJ11 (0.67) | KCNJ11ABCC9ABCC8KCNJ8CYP11B1 | |
| SCHEMBL4678184 | 0.93 | KCNJ11 (0.67) | KCNJ11ABCC9ABCC8KCNJ8CYP11B1 | |
| SCHEMBL13949268 | 0.93 | KCNJ11 (0.67) | KCNJ11ABCC9ABCC8KCNJ8CYP11B1 | |
| SCHEMBL4678874 | 0.91 | KCNJ11 (0.61) | KCNJ11ABCC9ABCC8KCNJ8CYP11B1 | |
| SCHEMBL4682725 | 0.91 | KCNJ11 (0.68) | KCNJ11ABCC9ABCC8KCNJ8CYP11B1 | |
| SCHEMBL4682731 | 0.91 | KCNJ11 (0.68) | KCNJ11ABCC9ABCC8KCNJ8CYP11B1 | |
| SCHEMBL4679042 | 0.91 | KCNJ11 (0.61) | KCNJ11ABCC9ABCC8KCNJ8CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1198456-B1 | POTASSIUM CHANNEL OPENERS | ABBOTT LAB (US) | 2007-09-19 | — | — | EP | claimed |
| US-6645968-B2 | E.g., N-(1-((anilinocarbonyl)amino)-2,2,2-trichloroethyl)-4-methyl-benzamide; antiepileptic, -ischemic and cardiotonic agents; sexual, eating and urogenital disorders; asthma; migraines; | ABBOTT LABORATORIES | 2003-11-11 | — | — | US | claimed |
| JP-2003506355-A | — | — | 2003-02-18 | — | — | JP | claimed |
| EP-1198456-A2 | POTASSIUM CHANNEL OPENERS | Abbott Laboratories (US) | 2002-04-24 | — | — | EP | claimed |
| US-20020028836-A1 | Potassium channel openers | ABBVIE INC. | 2002-03-07 | — | — | US | claimed |
| WO-2001009096-A2 | POTASSIUM CHANNEL OPENERS | ABBOTT LABORATORIES (US) | 2001-02-08 | — | — | WO | claimed |
| EP-1392655-B1 | POTASSIUM CHANNEL OPENERS | ABBOTT LAB (US) | 2008-07-16 | — | — | EP | disclosed |
| EP-1198456-B1 | POTASSIUM CHANNEL OPENERS | ABBOTT LAB (US) | 2007-09-19 | — | — | EP | disclosed |
| EP-1392655-A2 | POTASSIUM CHANNEL OPENERS | Abbott Laboratories (US) | 2004-03-03 | — | — | EP | disclosed |
| US-6645968-B2 | E.g., N-(1-((anilinocarbonyl)amino)-2,2,2-trichloroethyl)-4-methyl-benzamide; antiepileptic, -ischemic and cardiotonic agents; sexual, eating and urogenital disorders; asthma; migraines; | ABBOTT LABORATORIES | 2003-11-11 | — | — | US | disclosed |
| WO-2002062762-A2 | POTASSIUM CHANNEL OPENERS | ABBOTT LABORATORIES (US) | 2002-08-15 | — | — | WO | disclosed |
| EP-1198456-A2 | POTASSIUM CHANNEL OPENERS | Abbott Laboratories (US) | 2002-04-24 | — | — | EP | disclosed |
| US-20020028836-A1 | Potassium channel openers | ABBVIE INC. | 2002-03-07 | — | — | US | disclosed |
| WO-2001009096-A2 | POTASSIUM CHANNEL OPENERS | ABBOTT LABORATORIES (US) | 2001-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020028836-A1 | Potassium channel openers | KCNJ2, KCNJ11, KCNJ1 | KCNJ11 2/4885ABCC9 359/4885ABCC8 451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.